TOT BIOPHARM Co Ltd

Chinese oncology specialist TOT BIOPHARM has received approval from the country’s National Medical Products Administration for its Pusintin (bevacizumab) biosimilar to Avastin, “the first antibody d

The US market for initial public offerings may be transitioning to a less hospitable environment for biopharmaceutical firms, which have dominated the IPO market in recent years. Five drug developers

Californian companies secured nearly half the $15.7bn that US biotechs attracted from venture and private sources in 2018 (Also see " Biotech Sector Raises $23bn In Venture Capital In 2018 " - Scrip,

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmace